Sarah Boyce - 24 Aug 2022 Form 4 Insider Report for Avidity Biosciences, Inc. (RNA)

Role: President and CEO, Director
Signature: /s/ John W. Wallen III, Ph.D., J.D., Attorney-in-Fact
Issuer symbol: RNA
Transactions as of: 24 Aug 2022
Net transactions value: -$1,079,738
Form type: 4
Filing time: 26 Aug 2022, 19:29:59 UTC
Previous filing: 17 Aug 2022
Next filing: 03 Nov 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	RNA	Common Stock	Options Exercise	$43,456	+35,045		$1.24^*	35,045	24 Aug 2022	Direct	F1
transaction	RNA	Common Stock	Sale	$798,924	-35,045	-100%	$22.80	0	24 Aug 2022	Direct	F1, F2
transaction	RNA	Common Stock	Options Exercise	$18,420	+14,855		$1.24^*	14,855	25 Aug 2022	Direct	F1
transaction	RNA	Common Stock	Sale	$342,690	-14,855	-100%	$23.07	0	25 Aug 2022	Direct	F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	RNA	Stock Option (Right to Buy)	Options Exercise	$0	-35,045	-2.9%	$0.000000	1,161,870	24 Aug 2022	Common Stock	35,045	$1.24	Direct	F1, F4
transaction	RNA	Stock Option (Right to Buy)	Options Exercise	$0	-14,855	-1.3%	$0.000000	1,147,015	25 Aug 2022	Common Stock	14,855	$1.24	Direct	F1, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
F2	The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $22.45 to $23.05.The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3	The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $22.84 to $23.42.The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4	25% of the shares subject to the option vested on October 7, 2020 and 1/48th of the shares subject to the option will vest monthly thereafter.